Path ID: DB01142_MESH_D001714_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D004316 | doxepin | Drug |
| UniProt:P31645 | Sodium-dependent serotonin transporter | Protein |
| UniProt:P23975 | Sodium-dependent noradrenaline transporter | Protein |
| GO:0051610 | Serotonin uptake | BiologicalProcess |
| MESH:D012701 | Serotonin | ChemicalSubstance |
| GO:0051620 | Noradrenaline uptake | BiologicalProcess |
| MESH:D009638 | Noradrenaline | ChemicalSubstance |
| GO:0061533 | Norepinephrine secretion, neurotransmission | BiologicalProcess |
| GO:0060096 | Serotonin secretion, neurotransmission | BiologicalProcess |
| MESH:D001714 | Bipolar affective disorder, current episode depression | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Doxepin | DECREASES ACTIVITY OF | Sodium-Dependent Serotonin Transporter |
| Doxepin | DECREASES ACTIVITY OF | Sodium-Dependent Noradrenaline Transporter |
| Sodium-Dependent Serotonin Transporter | PARTICIPATES IN | Serotonin Uptake |
| Sodium-Dependent Noradrenaline Transporter | PARTICIPATES IN | Noradrenaline Uptake |
| Noradrenaline Uptake | DECREASES ABUNDANCE OF | Noradrenaline |
| Serotonin Uptake | DECREASES ABUNDANCE OF | Serotonin |
| Serotonin | POSITIVELY CORRELATED WITH | Serotonin Secretion, Neurotransmission |
| Noradrenaline | POSITIVELY CORRELATED WITH | Norepinephrine Secretion, Neurotransmission |
| Serotonin Secretion, Neurotransmission | NEGATIVELY REGULATES | Bipolar Affective Disorder, Current Episode Depression |
| Norepinephrine Secretion, Neurotransmission | NEGATIVELY REGULATES | Bipolar Affective Disorder, Current Episode Depression |
Comment: Oral doxepin is approved for the depression and/or anxiety, psychotic depressive disorders with associated anxiety and insomnia. The inhibition of norepinephrine and serotonin at synaptic nerve terminals by doxepin is beleived to be MoA
Reference: